Kluwer Patent Blog

Poland: Bolar Exemption, Supreme Court 23 October 2013

Krystyna Szczepanowska-Kozlowska (Allen & Overy) · Thursday, May 8th, 2014

The Bolar exemption must be interpreted narrowly in order not to affect the patent holder's exclusive rights. The privilege of the generic drug manufacturers who are allowed to conduct clinical trials in order to seek regulatory approval for their therapeutic products based on patented inventions does not apply to their third-party suppliers. Thus, manufacturing of patented pharmaceutical ingredients and offering them to generic drug companies constitutes patent infringement.

The full summary of this case has been published on Kluwer IP Law.

To make sure you do not miss out on regular updates from the Kluwer Patent Blog, please subscribe here.

Kluwer IP Law


The **2022 Future Ready Lawyer survey** showed that 79% of lawyers think that the importance of legal technology will increase for next year. With Kluwer IP Law you can navigate the increasingly global practice of IP law with specialized, local and cross-border information and tools from every preferred location. Are you, as an IP professional, ready for the future?

Learn how Kluwer IP Law can support you.

79% of the lawyers think that the importance of legal technology will increase for next year.

Drive change with Kluwer IP Law.

The master resource for Intellectual Property rights and registration.



2022 SURVEY REPORT
The Wolters Kluwer Future Ready Lawyer

Leading change

👀 Wolters Kluwer

This entry was posted on Thursday, May 8th, 2014 at 8:00 am and is filed under (Indirect) infringement, Case Law, Poland

You can follow any responses to this entry through the Comments (RSS) feed. Both comments and pings are currently closed.